Here are the 424B prospectus supplements from Wave Life Sciences Ltd. (WVE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow WVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WVE filings page.
Wave Life Sciences Ltd. is conducting a primary offering of 15,789,475 ordinary shares and pre-funded warrants to purchase 2,631,578 ordinary shares. The securities are priced at $19.00 per share and $18.9999 per pre-funded warrant, for a total public offering price of $349,999,744, with estimated net proceeds of approximately $328.4 million after underwriting discounts and expenses. The underwriters have a 30‑day option to buy up to an additional 2,763,157 ordinary shares, which would lift net proceeds to approximately $377.8 million.
The company plans to use the cash primarily to accelerate Phase 2 trials of WVE‑007, its INHBE GalNAc‑siRNA candidate for obesity, and for general corporate purposes. Recent interim Phase 1 data for WVE‑007 showed a single 240 mg dose produced a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat and a 3.2% increase in lean mass at three months, along with durable serum Activin E reductions greater than 75%. As of September 30, 2025, 160,288,481 ordinary shares were outstanding, rising to 176,077,956 on an as‑adjusted basis giving effect to this offering, and new investors face immediate net tangible book value dilution of $16.39 per share.